Skip to main content
    C

    CEL-SCI Corp (CVM)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • AMEX

    $1.66
    +0.38 (+29.69%)

    Market Cap: $22.51M

    Last updated: Nov 17, 2026 at 11:03 AM ET

    CEL-SCI Corp (CVM) Financials: Revenue, Profit and Cash Flow

    Updated Aug 14, 2026. Financial statements from company filings, amounts in US dollars.

    CEL-SCI reported revenue of $0 for the fiscal year ended Sep 30, 2025. That year, net income was -$25.41M, operating cash flow was -$17.12M and free cash flow was -$17.16M. The quarter ended Jun 30, 2026 had revenue of $0 and net income of -$5.67M.

    Revenue and Margins

    The company reported no revenue in the fiscal year ended Sep 2025, with an operating loss of $24.81M.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Sep 2025$0N/AN/AN/AN/A
    Sep 2024$0N/AN/AN/AN/A
    Sep 2023$0N/AN/AN/AN/A
    Sep 2022$0N/AN/AN/AN/A
    Sep 2021$0-100.0%N/AN/AN/A
    Sep 2020$558.66K+20.7%100.0%-5188.3%-5415.6%
    Sep 2019$462.75K-15.5%100.0%-4364.1%-4767.5%
    Sep 2018$547.45K+693.2%100.0%-3063.7%-5815.5%
    Sep 2017$69.02K-75.8%100.0%-31016.1%-20810.3%
    Sep 2016$285.06KN/A100.0%-8295.5%-4038.7%
    Annual, fiscal years ended Sep 2016 to Sep 2025

    Income Statement

    In the fiscal year ended Sep 2025, the net loss narrowed from the year before. In the quarter ended Jun 2026, the net loss widened from the same quarter a year earlier.

    Annual

    Line itemSep 2025Sep 2024Sep 2023Sep 2022Sep 2021Sep 2020Sep 2019Sep 2018Sep 2017Sep 2016
    Revenue$0$0$0$0$0$558.66K$462.75K$547.45K$69.02K$285.06K
    Gross profit$0$0$0$0$0$558.66K$462.75K$547.45K$69.02K$285.06K
    Research and development$15.89M$18.16M$22.47M$25.36M$23.11M$17.84M$12.66M$10.91M$15.61M$17.45M
    Operating income-$24.81M-$26.35M-$31.48M-$36.06M-$36.19M-$28.99M-$20.20M-$16.77M-$21.41M-$23.65M
    Net income-$25.41M-$26.92M-$32.19M-$36.70M-$36.36M-$30.26M-$22.06M-$31.84M-$14.36M-$11.51M
    EBITDA-$20.92M-$22.38M-$27.52M-$31.90M-$32.97M-$26.29M-$19.78M-$16.44M-$19.86M-$22.98M
    Fiscal years ended Sep 2016 to Sep 2025

    Quarterly

    Line itemJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Gross profit$0$0$0-$960.85K$0$0$0N/A$0$0$0-$998.65K
    Operating income-$5.56M-$5.33M-$5.37M-$6.03M-$5.49M-$6.39M-$6.89M-$6.12M-$6.67M-$7.08M-$6.49M-$7.47M
    Net income-$5.67M-$5.47M-$5.47M-$6.10M-$5.66M-$6.57M-$7.07M-$6.11M-$6.86M-$7.24M-$6.71M-$7.63M
    Last 12 quarters

    Balance Sheet

    As of Sep 2025, cash and equivalents exceeded short-term debt of $2.44M by $8.51M.

    Annual

    Line itemSep 2025Sep 2024Sep 2023Sep 2022Sep 2021Sep 2020Sep 2019Sep 2018Sep 2017Sep 2016
    Total assets$28.16M$26.99M$30.53M$50.52M$75.87M$40.54M$27.62M$29.59M$22.92M$24.89M
    Current assets$11.60M$6.06M$6.92M$25.44M$45.27M$17.70M$9.81M$11.44M$4.24M$5.46M
    Cash and equivalents$10.95M$4.74M$4.15M$22.67M$36.06M$15.51M$8.44M$10.31M$2.37M$2.92M
    Total liabilities$12.20M$14.12M$17.31M$18.36M$19.34M$20.81M$22.49M$29.59M$26.26M$25.57M
    Short-term debt$2.44M$2.24M$1.97M$1.73M$698.66K$1.07M$125.00K$843.46K$994.26K$0
    Long-term debtN/AN/AN/AN/AN/AN/AN/A$13.38M$13.21M$13.01M
    Shareholder equity$15.96M$12.87M$13.21M$32.16M$56.53M$19.73M$5.13M$916-$3.34M-$679.21K
    Fiscal years ended Sep 2016 to Sep 2025

    Quarterly

    Line itemJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total assets$21.36M$17.71M$22.89M$28.16M$20.34M$21.81M$25.70M$26.99M$24.07M$30.05M$28.71M$30.53M
    Total liabilities$10.40M$10.83M$11.76M$12.20M$13.31M$13.81M$14.39M$14.12M$15.60M$15.74M$16.06M$17.31M
    Cash and equivalents$6.53M$1.89M$6.28M$10.95M$1.79M$1.92M$4.61M$4.74M$384.65K$5.31M$3.24M$4.15M
    Shareholder equity$10.96M$6.87M$11.14M$15.96M$7.02M$8.00M$11.31M$12.87M$8.47M$14.30M$12.65M$13.21M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Sep 2025.

    Annual

    Line itemSep 2025Sep 2024Sep 2023Sep 2022Sep 2021Sep 2020Sep 2019Sep 2018Sep 2017Sep 2016
    Operating cash flow-$17.12M-$18.81M-$22.85M-$18.24M-$18.79M-$15.28M-$16.32M-$13.39M-$13.79M-$23.08M
    Capital expenditures$38.11K$94.88K$361.89K$637.89K$9.02M$2.65M$177.78K$1.01K$10.53K$31.41K
    Free cash flow-$17.16M-$18.91M-$23.21M-$18.88M-$27.80M-$17.93M-$16.50M-$13.39M-$13.80M-$23.11M
    Share repurchases$3.13M$2.37M$744.91K$169.44KN/A$752.80K$163.36K$195.59KN/AN/A
    Investing cash flow-$38.11K-$108.09K-$372.26K$5.49M-$15.18M-$2.69M-$335.84K-$58.14K-$17.00K-$34.22K
    Financing cash flow$23.37M$19.51M$4.69M-$638.43K$54.52M$25.04M$14.79M$21.39M$13.26M$20.31M
    Fiscal years ended Sep 2016 to Sep 2025

    Quarterly

    Line itemJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Operating cash flow-$4.03M-$4.02M-$4.02M-$4.67M-$3.94M-$4.37M-$4.14M-$4.82M-$4.58M-$4.53M-$4.89M-$5.04M
    Capital expendituresN/A$0$0$5.16K$2$1$32.95K$19.75K$23.47K$0$51.65K$10.37K
    Free cash flowN/A-$4.02M-$4.02M-$4.68M-$3.94M-$4.37M-$4.17M-$4.84M-$4.60M-$4.53M-$4.94M-$5.06M
    Last 12 quarters

    Frequently Asked Questions About CVM

    What is CEL-SCI's annual revenue?

    CEL-SCI reported revenue of $0 for the fiscal year ended Sep 30, 2025.

    Is CEL-SCI profitable?

    No. CEL-SCI reported net income of -$25.41M for the fiscal year ended Sep 30, 2025.

    How much free cash flow does CVM generate?

    For the fiscal year ended Sep 30, 2025, operating cash flow of -$17.12M minus capital expenditures of $38.11K produced free cash flow of -$17.16M.

    How much debt does CEL-SCI have?

    The balance sheet dated Sep 30, 2025 reported short-term debt of $2.44M and cash and equivalents of $10.95M.